[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490414":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":10,"responsibleParty":34,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":10,"enrollmentInfo":45,"targetDuration":48,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":10,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":10},{"fullName":5,"class":6},"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention",null,"Subjects with PAD treated with the PULSAR® -18 T3 Stent will be assessed for eligibility for the registry and consecutively included in the registry. Once informed consent is obtained, the required data will be collected.",[13],"Device: Stent PULSAR® -18 T3,",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Stent PULSAR® -18 T3,","Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and\u002For popliteal artery, primarily as salvage, in a population of patients residing in Spain and in \"real life\" conditions.",[9],[21],{"name":22,"affiliation":23,"role":24},"Jorge Cuenca Manteca, MD","Hospital Universitario Santa Lucía Murcia","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","968128600","jcuencam@gmail.com",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Maria Muñoz García","968381290","maria.munoz@imib.es",{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100490414","results-of-the-treatment-of-medium-and-long-de-novo-and-restenotic-lesions-in-the-superficial-femoral-artery-andor-popliteal-artery-with-primary-or-salvage-pulsar--18-t3-stent-100490414",false,"NCT05665816","Results of the Treatment of Medium and Long de Novo and Restenotic Lesions in the Superficial Femoral Artery and\u002For Popliteal Artery With Primary or Salvage Pulsar® -18 t3 Stent","T3PROJECT","Inclusion Criteria:\n\nI1. Patients with documented PAD from the AFS and\u002For AP, classified as having intermittent claudication or critical limb ischemia (CLI), with a Rutherford score between 3 and 5.\n\nI2. Age ≥ 55 years. I3. The target lesion consists of one or multiple de novo or restenotic lesions \\> 5 cm.\n\nI4. Adequate run-off distal circulation to the foot (at least one patent, pre-existing, or successfully restored native distal vessel before beginning treatment of the target lesion).\n\nI5. Adequate in-flow defined as, stenosis ≤ 30% of the diameter (either pre-existing or successfully reestablished before starting treatment of the target lesion).\n\nI6. CI signed and dated.\n\nExclusion Criteria:\n\nE1. Failure to successfully cross the target lesion with a guidewire (successful crossing means that the tip of the guidewire is distal to the target lesion, without dissection or perforation that limits blood flow).\n\nE2. Life expectancy \\\u003C 12 months.\n\nE3. Any contraindication to the use of antiplatelet therapy and\u002For heparin\n\nE4. Acute or subacute thrombosis in the target vessel.","ALL","55 Years",{"count":46,"type":47},100,"ESTIMATED","24 Months","OBSERVATIONAL","The purpose of this post-authorization registry is to describe the clinical outcomes of de novo and restenotic lesions in the superficial femoral and\u002For popliteal artery treated with the PULSAR® -18 T3 stent, implanted both primary and salvage.",[52],"Peripheral Artery Disease (PAD)","UNKNOWN","2022-12-26",{"date":56,"type":57},"2022-12-29","ACTUAL",{"date":59,"type":47},"2023-01-15",{"date":61,"type":47},"2024-05-15",{"name":5,"class":6}]